real world evidence
The paper discusses the potenital for collecting real-world data, recruiting patients and using APIs.
A frequent partner of biopharmas and the FDA, it has raised $94 million from investors since its commercial launch in 2015.
The original focus will be on multiple sclerosis but will extend to include Huntington's disease and hemophilia.